


ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund

(An Open Ended Equity Scheme following Pharma, Healthcare, Diagnostic and allied Theme.)

Category
Thematic

Style Box

Style



■ Diversified

Returns of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth Option as on July 31, 2021

Particulars	1 Year		3 Years		5 Years		Since inception	
	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000	CAGR (%)	Current Value of Investment of Rs. 10000
Scheme	42.47	14233.38	27.47	20710.76	-	-	27.51	20980.00
S&P BSE Healthcare TRI (Benchmark)	43.93	14378.18	23.41	18797.14	-	-	23.51	19040.10
Nifty 50 TRI (Additional Benchmark)	44.30	14415.96	12.90	14391.01	-	-	13.85	14853.10
NAV (Rs.) Per Unit (as on July 30, 2021 : 20.98)	14.74		10.13		-		10.00	

Notes:

- Different plans shall have different expense structure. The performance details provided herein are of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund.
- The scheme is currently managed by Dharmesh Kakkad. Mr. Dharmesh Kakkad has been managing this fund since May 2020. Total Schemes managed by the Fund Manager(Equity) is 9 (7 are jointly managed). Refer annexure at the following [link](#) for performance of other funds being managed by the fund managers.
- Date of inception: 13-Jul-2018.
- As the Scheme has completed more than 3 year but less than 5 years, the performance details of only since inception and 1 year are provided herein.
- Past performance may or may not be sustained in future and the same may not necessarily provide the basis for comparison with other investment.
- Load is not considered for computation of returns.
- In case, the start/end date of the concerned period is a nonbusiness date (NBD), the NAV of the previous date is considered for computation of returns. The NAV per unit shown in the table is as on the start date of the said period.
- The performance of the scheme is benchmarked to the Total Return variant of the Index.

Fund Details

Fund Managers** :

Dharmesh Kakkad
(Managing this fund since May, 2020 & Overall 11 years of experience)

Inception/Allotment date: 13-Jul-18

Monthly AAUM as on 30-Jun-21 : Rs. 2,819.41 crores
Closing AUM as on 30-Jun-21 : Rs. 2,923.84 crores

Application Amount for fresh Subscription :
Rs.5,000 (plus in multiple of Rs.1)

Min.Addl.Investment :
Rs.1,000 (plus in multiples of Re.1)

Exit load for Redemption / Switch out :- Lumpsum & SIP / STP Option:

1% of the applicable NAV - If units purchased or switched in from another scheme of the Fund are redeemed or switched out within 15 days from the date of allotment NIL - If units purchased or switched in from another scheme of the Fund are redeemed or switched out after 15 days from the date of allotment (w.e.f. 1st Jan 2019)

Total Expense Ratio @ @ :
Other : 2.20% p. a.
Direct : 1.17% p. a.

Indicative Investment Horizon: 5 years & above


NAV (As on 30-Jul-21): Growth Option : Rs. 20.98 | IDCW Option : 19.17 | Direct Plan Growth Option : Rs. 21.82 | Direct Plan IDCW Option : 19.99

Portfolio as on July 31, 2021

Company/Issuer	% to NAV	% to NAV Derivatives
Equity Shares	92.67%	2.29%
Healthcare Services	9.87%	
Fortis Healthcare Ltd.	3.10%	
Aster DM Healthcare Ltd.	2.79%	
Narayana Hrudayalaya Ltd.	1.88%	
Healthcare Global Enterprises Ltd.	1.08%	
Syngene International Ltd.	1.02%	
Insurance	1.77%	
SBI Life Insurance Company Ltd.	1.77%	
Pharmaceuticals	80.68%	2.29%
Sun Pharmaceutical Industries Ltd.	10.69%	
Cipla Ltd.	9.76%	
Alkem Laboratories Ltd.	7.71%	
Lupin Ltd.	6.91%	
Divi's Laboratories Ltd.	6.80%	
Dr. Reddy's Laboratories Ltd.	6.54%	2.29%
IPCA Laboratories Ltd.	5.92%	
Aurobindo Pharma Ltd.	4.41%	
Torrent Pharmaceuticals Ltd.	4.22%	
Sanofi India Ltd.	4.14%	
Indoco Remedies Ltd.	3.82%	
Glaxosmithkline Pharmaceuticals Ltd.	1.90%	
J.B.Chemicals & Pharmaceuticals Ltd.	1.84%	
Cadila Healthcare Ltd.	1.42%	
Biocon Ltd.	1.32%	
Dishman Carbogen Amcis Ltd.	1.13%	
FDC Ltd.	1.11%	
Natco Pharma Ltd.	1.04%	
Treasury Bills	0.34%	
91 Days Treasury Bill 2021 SOV	0.17%	
182 Days Treasury Bill 2021 SOV	0.17%	
Equity less than 1% of corpus	0.35%	
Short Term Debt and net current assets	4.71%	
Total Net Assets	100.00%	

• Top Ten Holdings Securities and the corresponding derivative exposure with less than 1% to NAV, have been clubbed together with a consolidated limit of 10%. Derivatives are considered at exposure value.

Top Sectors



Quantitative Indicators


Average P/E : 38.98 | Average P/B : 6.11 | Average Dividend Yield : 0.65

Annual Portfolio Turnover Ratio : Equity - 0.48 times

Std Dev (Annualised) : 21.05% | Sharpe Ratio : 1.10 | Portfolio Beta : 0.90

The figures are not netted for derivative transactions.
Risk-free rate based on the last Overnight MIBOR cut-off of 3.40%
@@ Total Expense Ratio is as on the last business day of the month.
**In addition to the fund manager managing this fund, overseas investment is managed by Ms. Priyanka Khandelwal.
To Refer to the annexure for details on option, entry load, SWP, STP/Flex STP/Value STP & minimum redemption amount pertaining to the scheme. [Click here](#)
To Refer to the annexure for details on scheme objective, IDCW history and SIP details. [Click here](#)

Riskometer



ICICI Prudential Mutual Fund Corporate Office

ONE BKC, A - Wing, 13th Floor, Bandra-Kurla Complex, Mumbai 400 051, India.

Tel: 022 - 26525000 Fax: 022 - 26528100, website: www.icicipruamc.com, email id: enquiry@icicipruamc.com

Statutory Details & Risk Factors

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

Disclaimer: In the preparation of the material contained in this document, the Asset Management Company (AMC) has used information that is publicly available, including information developed in-house. Some of the material used in the document may have been obtained from members/persons other than the AMC and/or its affiliates and which may have been made available to the AMC and/or to its affiliates. Information gathered and material used in this document is believed to be from reliable sources. The AMC however does not warrant the accuracy, reasonableness and / or completeness of any information. We have included statements / opinions / recommendations in this document, which contain words, or phrases such as "will", "expect", "should", "believe" and similar expressions or variations of such expressions that are "forward looking statements". Actual results may differ materially from those suggested by the forward looking statements due to risk or uncertainties associated with our expectations with respect to, but not limited to, exposure to market risks, general economic and political conditions in India and other countries globally, which have an impact on our services and / or investments, the monetary and interest policies of India, inflation, deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices etc.

The AMC (including its affiliates), the Mutual Fund, the trust and any of its officers, directors, personnel and employees, shall not be liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner. The recipient alone shall be fully responsible/are liable for any decision taken on this material.